Publications

ZW171

Categories
Search
Clinical, ZW171
June 2, 2025
ASCO
Design of a First-in-Human Multicenter Open-Label Study of ZW171, a Mesothelin x CD3–Targeting Bispecific T Cell Engager, in Participants With Advanced Solid Tumors: ZWI-ZW171-101
Johnson et al.
ZW171
April 28, 2025
AACR
ZW171, a differentiated 2+1 T cell-engaging bispecific antibody with antitumor activity in a range of mesothelin-expressing cancers
Afacan et al.
Preclinical, ZW171
November 9, 2024
SITC
Mechanistic QSP modeling and translational strategy for determining an FIH dose for ZW171, a bispecific 2+1 T-cell engager molecule targeting mesothelin and CD3
Charles Chen
ZW171
May 19, 2023
PEGS
Engineering and Preclinical Development of ZW171: A 2+1 Format Anti-MSLN T Cell Engager
Piscitelli et al.
ZW171
April 17, 2023
AACR
ZW171, a T Cell-Engaging, Bispecific Antibody for the Treatment of Mesothelin-Expressing Solid Tumors
Afacan et al.